Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CTI Reports Pixantrone Clinical Studies
Cell Therapeutics (CTI) has reported pixantrone clinical studies, including follow-up data and subgroup analyses of high risk patients, from the phase-III Extend Pix 301 clinical trial of pixantrone
Cell Therapeutics (CTI) has reported pixantrone clinical studies, including follow-up data and subgroup analyses of high risk patients, from the phase-III Extend Pix 301 clinical trial of pixantrone
For the fiscal 2009, profit from continuing activities rose to GBP4.2 million from GBP2.8 million in the previous year. Earnings per share from continuing operations were 16.166 pence
In February 2008, the US District Court for the Central District of California awarded CombiMatrix $31.2 Million in its lawsuit against National Union Fire Insurance Company of Pittsburg,
Merck KGaA has initiated its global phase-III clinical study of the therapeutic cancer vaccine Stimuvax (BLP25 liposome vaccine, L-BLP25) in patients with advanced, inoperable breast cancer. Stimuvax is
Neovacs plans to initiate a phase-II study of its TNF Kinoid, subject to regulatory consent, in rheumatoid arthritis patients who have failed treatment with at least one TNF
China Sky One Medical (CSOM) has received approvals from the State Food and Drug Administration (SFDA) in China, for the production of Geranium ointment and Musk liniment for
Cordex has signed an agreement with Clinical Trials International (CTI), regarding a license to develop and market Cordex’s drug candidate ATPotent. ATPotent is a novel ATP-based drug candidate
Wyeth has exercised its option under the terms of its collaboration agreement with Trubion, to extend the research period for an additional one-year period through Dec. 22, 2010.
BRAHMS, Cezanne, and Lumiphore have signed an agreement to incorporate Lumiphore’s Lumi4 -Tb complexes in BRAHMS diagnostic tests. Lumi4-Tb would increase sensitivity of BRAHMS diagnostic tests and allow
Amicus has initiated phase-III trial with its investigational drug, Amigal (migalastat hydrochloride), for the treatment of Fabry disease. The company has reached an agreement with FDA on the